1. Home
  2. NP vs TARS Comparison

NP vs TARS Comparison

Compare NP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NP

Neptune Insurance Holdings Inc.

N/A

Current Price

$24.47

Market Cap

2.9B

Sector

Finance

ML Signal

N/A

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$70.20

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NP
TARS
Founded
2017
2016
Country
United States
United States
Employees
58
N/A
Industry
Specialty Insurers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NP
TARS
Price
$24.47
$70.20
Analyst Decision
Buy
Buy
Analyst Count
12
6
Target Price
$27.04
$89.00
AVG Volume (30 Days)
325.5K
409.6K
Earning Date
04-29-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.21
EPS
N/A
N/A
Revenue
N/A
$451,360,000.00
Revenue This Year
$25.45
$55.67
Revenue Next Year
$15.74
$30.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
146.71
52 Week Low
$14.78
$38.51
52 Week High
$31.75
$85.25

Technical Indicators

Market Signals
Indicator
NP
TARS
Relative Strength Index (RSI) 62.48 54.02
Support Level $24.29 $65.62
Resistance Level $26.85 $78.34
Average True Range (ATR) 1.42 3.04
MACD 0.37 0.25
Stochastic Oscillator 91.47 81.80

Price Performance

Historical Comparison
NP
TARS

About NP Neptune Insurance Holdings Inc.

Neptune Insurance Holdings Inc is a high-growth, data-driven MGA that is revolutionizing the way homeowners and businesses protect against the growing risks of flooding. It offers a range of easy-to-purchase residential and commercial insurance products - including primary flood insurance, excess flood insurance, and parametric earthquake insurance - distributed through a nationwide network of agencies. It underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies, whom the company refer to as capacity providers, that manage both this risk and the associated claims handling.

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Share on Social Networks: